Ophthotech (OPHT), whose IPO is scheduled for September 26th, offers a completely new approach to a common problem. The lead compound, Fovista, promises to dramatically change the treatment of age-related macular degeneration and it has performed outstandingly in phase 1 and phase 2 trials. In this article, I discuss the basic science (with a few minor glosses), the clinical trials, and -- of course -- valuations. At $490 million, Ophthotech is a bargain.
The macula is a pigmented spot on the retina responsible for high-acuity central vision. Consequently, disorders of the macula are severely disabling.
Figure 1. Fundoscopic view of the normal retina. Open-source image adapted from Wikipedia.
Macular degeneration is a process of...
Only subscribers can access this article, which is part of the PRO research library covering 3,584 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: